Analysis of ROR1 protein expression in human cancer and normal tissues.

CONCLUSIONS: ROR1 is a promising immunotherapeutic target in many epithelial tumors, however high cell-surface ROR1 expression in multiple normal tissues raises concerns for on-target off-tumor toxicities. Clinical translation of ROR1 targeted therapies warrants careful monitoring of toxicities to normal organs, and may require strategies to ensure patient safety. PMID: 27852699 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/27852699?dopt=Abstract

Source: Clinical Cancer Research - November 15, 2016 Category: Cancer & Oncology Authors: Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, Berger C, Kosasih PL, Rajan A, Sommermeyer D, Porter P, Riddell SR Tags: Clin Cancer Res Source Type: research